The CXCR4 protein, a crucial G protein coupled receptor expressed on the cell membrane, exhibits high expression in TNBC compared to other subtypes of breast cancer, and is correlated with unfavorable prognostic outcomes.[16] Therefore, CXCR4 represents an optimal guidance target in TNBC and its small molecule inhibitor AMD3100 approved by FDA in 2008 is chosen to link to the nanoparticles. The gene discussed is CXCR4; the disease is breast carcinoma.